Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development

Patrizia Dell'Era, Roberto Ronca, Laura Coco, Stefania Nicoli, Marco Metra, Marco Presta

Abstract—Fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling plays a crucial role in mesoderm formation and patterning. *Heartless* mutant studies in *Drosophila* suggest that FGFR1, among the different FGFRs, may play a role in cardiogenesis. However, $fgfr1^{-/-}$ mice die during gastrulation before heart formation. To establish the contribution of FGFR1 in cardiac development, we investigated the capacity of murine $fgfr1^{+/-}$ and $fgfr1^{-/-}$ embryonic stem (ES) cells to differentiate to cardiomyocytes in vitro. Clusters of pulsating cardiomyocytes were observed in >90% of 3-dimensional embryoid bodies (EBs) originated from $fgfr1^{+/-}$ ES cells at day 9 to 10 of differentiation. In contrast, 10% or less of $fgfr1^{-/-}$ EBs showed beating foci at day 16. Accordingly, $fgfr1^{-/-}$ EBs were characterized by impaired expression of early cardiac transcription factors *Nkx2.5* and *d-Hand* and of late structural cardiac genes *myosin heavy chain* (*MHC*)-α, *MHC*-β, and *ventricular myosin light chain*. Homozygous *fgfr1* mutation resulted also in alterations of the expression of mesoderm-related early genes, including *nodal, BMP2, BMP4, T(bra)*, and *sonic hedgehog*. Nevertheless, $fgfr1^{+/-}$ and $fgfr1^{-/-}$ EBs similarly express cardiogenic precursor, endothelial, hematopoietic, and skeletal muscle markers, indicating that *fgfr1*-null mutation exerts a selective effect on cardiomyocyte development in differentiating ES cells. Accordingly, inhibitors of FGFR signaling, including the FGFR1 tyrosine kinase inhibitor SU 5402, the MEK1/2 inhibitor U0126, and the protein kinase C inhibitor GF109 all prevented cardiomyocyte differentiation in $fgfr1^{+/-}$ EBs without affecting the expression of the hematopoietic/endothelial marker *flk-1*. In conclusion, the data point to a nonredundant role for FGFR1-mediated signaling in cardiomyocyte development. (*Circ Res*. 2003;93:414-420.)

Key Words: fibroblast growth factor receptor ∎ cardiomyocytes ∎ embryonic stem cells

F ibroblast growth factor receptors (FGFRs) belong the subclass IV of membrane-spanning tyrosine kinase (TK) receptors.[1,2] Four *fgfr* genes have been identified.[3] FGFR1–4 proteins share common structural features[4] and interact with the members of the FGF family composed of at least 23 polypeptides.[5] The FGF/FGFR system has been implicated in a variety of physiological and pathological conditions, including embryonic development, tissue growth and remodeling, inflammation, tumor growth, and vascularization.[3]

After ligand binding and receptor dimerization, a number of tyrosine autophosphorylation sites have been identified in FGFR1[6]: Y463 is responsible for Crk binding[7]; Y653/654 are critical for TK activity; and Y766 is responsible for phospholipase C-γ (PLC-γ) and Shb binding.[8,9] Activated PLC-γ hydrolyzes membrane phospholipids, generating inositol 1,4,5-trisphosphate and diacylglycerol that activates certain protein kinase C (PKC) isoforms.[10] Also, FGFR1 activation leads to FRS2 phosphorylation,[11] followed by Grb2 and Shp-2 interactions that are required for activation of the Ras/Raf-1/MEK/ERK pathway cascade.[12]

FGF/FGFR signaling plays important functions in mesoderm formation and development.[13] Accordingly, $fgfr1^{-/-}$

mice die during gastrulation, displaying defective mesoderm patterning with reduction in the amount of paraxial mesoderm and lack of somite formation.[14,15] Studies on chimeric embryos using FGFR1-deficient embryonic stem (ES) cells revealed a early defect in the mesodermal and endodermal cell movement through the primitive streak, followed by deficiencies in contributing to anterior mesoderm, including heart tissue.[16,17] Moreover, FGFR1 has been implicated in embryonic anterior-posterior axis patterning.[18]

The heart is the first organ to be formed in vertebrate embryo development. Precardiac mesoderm cells become allocated at or shortly after gastrulation, leading to the formation of a single beating linear heart tube that undergoes right-ward looping followed by segmentation and growth of cardiac chambers.[19] Commitment to a cardiac fate results from inductive interactions during gastrulation. In amphibian and avian embryos, the endoderm adjacent to the mesodermal cardiac precursors is the source of instructive signaling capable of specifying a cardiac fate.[20–22] In this context, FGF family members, in cooperation with members of the transforming growth factor-β family, play a pivotal role.[20,22–25]

FGF/FGFR signaling drives cardiac differentiation also in *Drosophila* where the cardiac counterpart is the contractile dorsal vessel. Fly cardiac progenitor cells are characterized by the expression of *tinman*, a transcription factor of the NK homeobox protein family.[26] Mesoderm spreading depends on the expression of *heartless*, homologous to vertebrate *fgfr1*.[27,28] *Heartless* mutant embryos, like *tinman* mutants, do not develop the dorsal vessel.[27,29] Finally, FGFRs are present in rodent embryonic heart[30,31] and *fgf8* expression is required for induction and patterning of myocardial precursors in zebrafish.[32]

Taken together, several studies point to the importance of FGF/FGFR signaling in heart development. In particular, *heartless* mutant studies in *Drosophila* suggest that FGFR1 may play a nonredundant role in cardiogenesis. Accordingly, previous analysis on mouse chimeras showed deficiencies of *fgfr1*[−/−] ES cells in contributing to heart tissue.[21] However, the early embryonic lethality observed in *fgfr1*[−/−] mice occurs before a stage in which the role of FGFR1 in murine cardiogenesis can be evaluated.

Pluripotent ES cells differentiate into a variety of cell lineages in vitro after aggregation into 3-dimensional structures termed embryoid bodies (EBs).[33] EBs originate a variety of specialized cell types, including cardiomyocytes that are manifested by the appearance of spontaneously contracting foci.[34] Thus, ES cell differentiation in EBs can be used to study the impact of specific gene inactivation during cardiomyocyte development also for those loss of function mutations resulting in early embryonic lethality.[35] On this basis, to investigate the contribution of FGFR1 in murine cardiomyocyte development, we studied the differentiation of EBs originating from murine *fgfr1*[−/−] ES cells.

The data demonstrate the absence of contracting cardiomyocyte foci and of specific cardiac gene transcripts in differentiating *fgfr1*[−/−] EBs, pointing to a crucial role for FGFR1 in heart development.

Materials and Methods

ES Cell Culture and Differentiation

Murine 11-22 *fgfr1*[+/−], 23-46 *fgfr1*[−/−], and 23-18 *fgfr1*[−/−] ES cells[15] were adapted to grow without feeder cells and maintained in Dulbecco's Modified Eagle's Medium supplemented with 20% fetal bovine serum (Hyclone), 0.1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 0.1 mmol/L β-mercaptoethanol, 2 mmol/L L-glutamine, and 1000 U/mL LIF (ESGRO, Chemicon).

Differentiation experiments were performed in parallel on 11-22 *fgfr1*[+/−] and 23-46 *fgfr1*[−/−] cells. At T_0 of differentiation, exponentially growing ES cells were resuspended in LIF-deprived (EB) medium and cultured in 30 μL hanging drops (400 cells) for 2 days to allow cell aggregation. Then, aggregates were transferred onto 0.7% agarose-coated dishes and grown for 5 days in EB medium. At day 7, EBs were transferred into 24-well tissue culture plates, one aggregate per well, and allowed to adhere. Aggregates were monitored for the appearance of spontaneously contracting foci during the following 9–10 days. When indicated, EBs were immunostained for cardiac α-myosin heavy chain expression (see expanded Materials and Methods section in the online data supplement available at http://www.circresaha.org).

RNA Extraction and Semiquantitative RT-PCR Analysis

Total RNA was extracted from ES cells as described.[36] Two μg of total RNA were retrotranscribed with Ready-To-Go You-Prime First


Figure 1. FGFR and FGF expression in *fgfr1*[+/−] and *fgfr1*[−/−] EBs. Total RNA was extracted from undifferentiated *fgfr1*[+/−] and *fgfr1*[−/−] ES cells (T_0) and from EBs at different times after LIF withdrawal. Equivalent amounts of cDNA were amplified by PCR. The *tubulin* gene was used for normalization.

Strand Beads (Amersham Biosciences), using a 18 mer oligo-dT primer in a 20-μL volume. For each transcript, 2 μL of the retrotranscribed RNA were subjected to polymerase chain reaction using Pre-Aliquoted ReadyMix PCR Master Mix (Abgene) under the following conditions: 94°C (30 seconds), 60°C (30 seconds) for all transcripts with the exception of *fgfr1* (72°C), *Oct4* (64°C), and 72°C (1 minute). Oligonucleotide primers and the number of PCR cycles are listed in the online Table (online data supplement). In order to compare multiple gene expression, several independent RT reactions were mixed together before PCR. The data were then confirmed by analyzing the RNA extracted from two or more independent differentiation experiments. Titration analysis of PCR amplification of *tubulin* and *Nkx2.5* mRNAs confirmed that the adopted conditions allowed a semiquantitative analysis of gene expression (online Figure in the online data supplement).

Results

FGF and FGFR Expression During In Vitro Differentiation of *fgfr1*[+/−] and *fgfr1*[−/−] ES Cells

The 11-22 *fgfr1*[+/−] ES cell line was obtained by homologous recombination, replacing *fgfr1* exon 4 with *PGKneo*. The two related *fgfr1*[−/−] ES cell lines were then generated by targeting the remaining wild-type allele with pFGFR1*hyg*.[15] *Fgfr1*[+/−] mice are normal in terms of growth, morphology, health, and fertility.[15] Accordingly, the in vitro differentiation process of *fgfr1*[+/−] EBs resembles that of wild-type EBs with a similar expression of several markers belonging to cellular lineages derived from all the three embryonic layers (see below and data not shown). On this basis, cardiomyocyte differentiation was compared in *fgfr1*[+/−] versus *fgfr1*[−/−] ES cells throughout the present study. *Fgfr1*[+/−] and *fgfr1*[−/−] ES cells are morphologically indistinguishable, have similar rates of growth in vitro, and can originate muscle cells when injected in nude mice to form teratomas.[15]

Preliminarily, we evaluated the expression of FGFRs and FGFR ligands implicated in early development during in vitro differentiation of *fgfr1*[+/−] and *fgfr1*[−/−] EBs (Figure 1). In *fgfr1*[+/−] EBs, all FGFRs showed a maximal expression between days 7 and 10 of differentiation. In contrast, together with the anticipated lack of *fgfr1* expression, no *fgfr4* transcripts were detectable in *fgfr1*[−/−] EBs that showed also a delayed expression of *fgfr2* and *fgfr3*. Moreover, differenti-

Figure 2. A, Cardiomyocyte formation in *fgfr1*[+/−] and *fgfr1*[−/−] EBs. EBs originated from *fgfr1*[+/−] (filled squares) and *fgfr1*[−/−] (open circles) ES cells were transferred at day 7 after LIF withdrawal in 24-well culture plates (↑), one body per well. Percentage of EBs with spontaneously contracting foci was counted under an inverted microscope. Each point (n≥50) is the mean±SD of 3 independent experiments. B, Semiquantitative RT-PCR analysis of the expression of cardiac markers in EBs. Total RNA was extracted from undifferentiated *fgfr1*[+/−] and *fgfr1*[−/−] ES cells (T_0) and from EBs at different times after LIF withdrawal. Equivalent amounts of cDNA were amplified by PCR. The *tubulin* gene was used for normalization. C, Immunolocalization of MHC-α in *fgfr1*[+/−] and *fgfr1*[−/−] EBs at day 10. EB sections were decorated with anti–MHC-α antibodies (a and b) and cell nuclei were counterstained with DAPI (c and d).

ating *fgfr1*[+/−] EBs were characterized by the rapid disappearance of *fgf4* expression that was paralleled by the transient expression of *fgf10* between days 7 and 10 and by the late increase in *fgf8* transcript levels. Homozygous *fgfr1* mutation resulted instead in sustained *fgf4* expression and lack of *fgf10* upregulation in differentiating EBs that also showed an earlier increase in *fgf8* expression (Figure 1).

Contractile Cardiomyocyte Foci in *fgfr1*[+/−] and *fgfr1*[−/−] EBs

At day 7 of differentiation, *fgfr1*[+/−] and *fgfr1*[−/−] EBs were allowed to adhere and monitored during the following 13 days for the appearance of clusters of spontaneously pulsating cardiomyocytes. *Fgfr1*[+/−] and *fgfr1*[−/−] ES cell aggregates showed a similar capacity to attach to the substrate. More than 50% of *fgfr1*[+/−] EBs generated contracting foci one day after attachment. The percentage of beating foci increased up to 90% at day 9–10 to decrease slowly after day 16 (Figure 2A). In contrast, *fgfr1*[−/−] EBs showed a dramatic decrease in the capacity to generate contractile foci, with no more than 10% of EBs showing beating areas after 16 days of differentiation. Moreover, the few contractile *fgfr1*[−/−] EBs never showed more than one beating focus per EB, whereas two or more foci were constantly observed in the majority of heterozygous EBs. Also, the beating frequency was significantly reduced in *fgfr1*[−/−] EBs compared with *fgfr1*[+/−] EBs (47±6 and 99±9 bpm, respectively).

Similar results were obtained with EBs originated from 100 to 800 cells per aggregate or when aggregates were allowed to attach to various substrata, including gelatin, type I collagen, laminin, vitronectin, fibronectin, or Matrigel. Also, changes in the pH of the cell culture medium (from 6.7 to 8.7), treatment with the cardiomyocyte-inducing compound 5-azacytidine,[37] or induction of hypoxia-like conditions after treatment with CoCl₂[38] did not induce the appearance of contractile areas in *fgfr1*[−/−] ES cells (data not shown). Thus, *fgfr1* loss of function dramatically affects the capacity to originate the formation of contractile cardiomyocyte foci in

differentiating EBs in a variety of experimental conditions. Similar results were obtained for the 23-18 *fgfr1*[−/−] ES cell line, further supporting these conclusions (data not shown).

Expression of Cardiac Markers in *fgfr1*[+/−] and *fgfr1*[−/−] EBs

ES-derived cardiomyocytes express cardiac gene products during EB differentiation in a developmentally controlled manner that closely recapitulates the developmental pattern of early cardiogenesis.[39] To gain insights on the developmental alterations responsible for the lack of contractile foci in *fgfr1*[−/−] EBs, we evaluated the expression of early and late myocardial genes during EB differentiation (Figure 2B). Between days 7 and 10, *fgfr1*[+/−] EBs showed a peak of expression of the early cardiac gene *Nkx2.5*, homologous to the *Drosophila* gene *tinman*,[40] and of the cardiac transcription factors *d-Hand*, *e-Hand*, *GATA-4*, and *Irx4*.[41–44] This was followed by the upregulation of genes encoding for the myocardial structural proteins myosin heavy chain (MHC)-α, MHC-β, and ventricular myosin light chain (MLC-2V).[45] In contrast, homozygous EBs were characterized by the lack of *Nkx2.5* expression, by delayed *d-Hand*, *e-Hand*, and *GATA-4* expression, and by a prolonged *Irx4* upregulation (Figure 2B). This was paralleled by the absence of *MHC-α*, *MHC-β*, and *MLC-2V* transcripts throughout the whole experimental period. Accordingly, no MHC-α immunoreactivity was observed in *fgfr1*[−/−] EBs (Figure 2C).

Expression of Mesoderm-Related Genes in *fgfr1*[+/−] and *fgfr1*[−/−] EBs

To assess whether the lack of cardiomyocyte formation in *fgfr1*[−/−] EBs is related to a more general effect on mesodermal differentiation, we compared differentiating *fgfr1*[+/−] and *fgfr1*[−/−] ES cells for the expression of genes involved in early stages of mesoderm formation (Figure 3). *Oct4*, *nodal,* and *cripto1* expression are promptly downregulated in *fgfr1*[+/−] EBs after LIF withdrawal. In parallel, the expression of the cardiogenic mesodermal marker *Mef2c*[46,47] progressively in-

Figure 3. Semiquantitative RT-PCR analysis of the expression of early (top) and late (bottom) mesodermal markers during *fgfr1+/−* and *fgfr1−/−* ES cell differentiation.


Figure 4. Role of FGF/FGFR signaling in cardiomyocyte differentiation in EBs. A, After LIF withdrawal, heterozygous *fgfr1+/−* ES cell aggregates were incubated with vehicle, 50 µmol/L of SU5402, 10 µmol/L of U0126, or 2 µmol/L of GF109. At day 9, the frequency of beating EBs was scored and total RNA was extracted from the different cell cultures. B, After LIF withdrawal, homozygous *fgfr1−/−* ES cell aggregates were incubated with vehicle (open squares), 50 nmol/L PMA (filled circles), or 50 nmol/L PMA plus 10 µmol/L U0126 (open triangles). Frequency of beating EBs was scored daily and total RNA was extracted from the different cell cultures at day 14. In both experiments, expression of the cardiac marker *MLC-2V* and of the hematopoietic/endothelial marker *flk-1* was evaluated by semiquantitative RT-PCR analysis (insets). In both insets, T$_0$ shows the expression of the investigated genes in the corresponding undifferentiated ES cells.

creases during differentiation. Also, *BMP2*, *BMP4*, *T(bra)*, and *sonic hedgehog* (*SHH*) expression are upregulated after LIF withdrawal with different kinetics. Homozygous *fgfr1* mutation did not hamper the capacity of ES cells to undergo differentiation (as shown by *Oct4* downregulation) and to originate cardiogenic precursors (as shown by *Mef2c* induction), although an apparent general delay in the modulation of some mesoderm-related genes was observed. Indeed, *fgfr1−/−* EBs were characterized by the following: (1) the persistent expression of *nodal*; (2) the delayed and/or prolonged expression of *BMP2* and *BMP4*; (3) the strong and persistent upregulation of *T(bra)*; and (4) the reduced increase in *SHH* expression.

Despite these differences in the expression of early mesodermal markers, both *fgfr1+/−* and *fgfr1−/−* EBs showed similar expression patterns for genes characterizing different mesodermal-derived lineages (Figure 3). Indeed, the hematopoietic/endothelial markers vascular endothelial growth factor receptor *flk-1*, *CD34*, and *c-kit*,[48–50] and the later endothelial [*CD31* and *vascular endothelial cadherin* (*ve-cad*)] and hematopoietic (*β-major*) markers were similarly expressed in the two differentiating ES cell lines. Also, both cell lines express the skeletal muscle markers *myogenin* and *myoD* at day 16 of differentiation (data not shown).

Role of FGF/FGFR Signaling in Cardiomyocyte Development in *fgfr1+/−* and *fgfr1−/−* EBs

To confirm the role of FGFR1 in cardiomyocyte development, *fgfr1+/−* ES cells were treated with inhibitors of FGF/FGFR signaling during differentiation. Both FGFR1 TK inhibitor SU 5402[51] and MEK1/2 inhibitor U0126[52] hamper pulsating cardiomyocytes formation and the upregulation of the cardiac marker *MLC-2V* in *fgfr1+/−* EBs without affecting

hematopoietic/endothelial marker *flk-1* expression (Figure 4A). In contrast, the MEK1 inhibitor PD098059[52] does not affect cardiomyocyte differentiation (data not shown and reference[53]). Interestingly, U0126 and PD098059 do not affect *BMP2* and *BMP4* expression (data not shown).

PKC isozymes regulate the Ras/Raf-1/MEK/ERK cascade at different levels.[54] The classical/novel PKC inhibitor GF109[55] prevented the formation of pulsating foci and *MLC-2V* upregulation in *fgfr1+/−* EBs without affecting *flk-1* expression (Figure 4A). Also, using a nonexhaustive library of Antennapedia carrier-conjugated peptides that selectively inhibit translocation of the different PKC isozymes,[56] we observed a 24-hour delay in beating foci appearance in *fgfr1+/−* EBs maintained in the presence of the selective PKCε antagonist (data not shown).

To further investigate the cross-talk between the PKC and the MEK/ERK signaling pathways in cardiogenesis, we assessed the effect of the PKC activator phorbol ester PMA on cardiomyocyte development in *fgfr1−/−* EBs (Figure 4B). PMA treatment partially rescued cardiomyocyte differentiation in these cells, more than 60% of EBs showing beating areas after 14 days of differentiation. The appearance of beating foci was paralleled by *MLC-2V* upregulation (Figure 4B, inset). The effect of PMA was abolished by cotreatment with U0126, thus indicating that PKC may act upstream of ERK activation during cardiomyocyte development in EBs. Again, PMA treatment in the absence or in the presence of U0126 had no effect on *flk-1* expression (Figure 4B, inset).

Discussion

Experimental evidence on various animal species point to a role for FGF/FGFR signaling in heart development. Homozygous *fgfr1*-null mice display early growth defects and alterations in mesoderm patterning.[14,15] However, the early embryonic lethality observed in these animals did not allow to assess the role of FGFR1 in murine cardiogenesis. In the present study, differentiating EBs from murine *fgfr1*[−/−] ES cells fail to form contractile cardiomyocyte foci and do not express early and late cardiac markers. This occurs despite the ability of *fgfr1*[−/−] EBs to generate cardiogenic precursors, as evidenced by the upregulation of *Mef2c* expression[46,47] after LIF withdrawal. Also, inhibitors of FGF/FGFR signaling, including TK-FGFR1, MEK1/2, and PKC inhibitors, all prevented cardiomyocyte differentiation in phenotypically normal *fgfr1*[+/−] EBs. Conversely, the PKC activator PMA partially restored the ability of *fgfr1*[−/−] EBs to form contractile foci. Finally, lentivirus-mediated FGFR1 overexpression totally rescues cardiomyocyte formation in *fgfr1*[−/−] ES cells (P. Dell'Era, unpublished data, 2003). Taken together the data point to a nonredundant role for FGFR1 in cardiomyocyte differentiation in murine EBs. This conclusion extends previous observations on the lack of dorsal vessel formation in *Drosophila heartless* mutants[27,28] and the reduced contribution of *fgfr1*[−/−] ES cells to heart tissue development in mouse embryo chimeras.[16]

During in vitro differentiation, ES-derived cardiomyocytes express cardiac gene products in a developmentally controlled manner.[34] The transcription factors *Nkx2.5* and *d-Hand* are coexpressed in the precardiac mesoderm and during early tube formation and control distinct developmental events during cardiogenesis.[57] We observed a transient early expression of *Nkx2.5* and *d-Hand* in differentiating *fgfr1*[+/−] EBs. This was accompanied by the expression of the left-ventricular gene *e-Hand*, the cardiac transcription factor *GATA-4*, and the ventricle-specific homeobox gene *Irx4*.[41–43]. Then, in parallel with the appearance of contractile foci, *fgfr1*[+/−] EBs expressed the myocardial structural genes *MHC-α*, *MHC-β*, and *MLC-2V*. In contrast, homozygous EBs failed to express *Nkx2.5*. In *Nkx2.5*-null mice, the heart tube forms, but morphological defects are observed at the looping stage and several cardiac genes are downregulated.[58] Accordingly, *fgfr1*[−/−] EBs showed a delayed expression of *d-Hand*, *e-Hand*, and *GATA-4* genes, and a prolonged *Irx4* upregulation. Finally, the absence of *MHC-α*, *MHC-β*, and *MLC-2V* transcripts is in keeping with the lack of contractile cardiomyocyte foci in *fgfr1*-null EBs. Thus, the data indicate that *fgfr1* inactivation dramatically affects the expression of several cardiac transcription factors with a consequent impairment on the expression of structural myocardial genes and contractile foci formation. Preliminary data indicate the capacity of recombinant FGF2 to upregulate *Nkx2.5* expression in FGFR1-expressing murine endothelial cell cultures (Figure 5). This suggests that *Nkx2.5* may represent one of the earliest direct FGF/FGFR targets during heart development and that FGFR1 may mediate cardiomyocyte development in EBs by activating *Nkx2.5* expression in *Mef2c*[+] cardiogenic mesodermal cells.


Figure 5. *Nkx2.5* upregulation by FGF2 in endothelial cells. Murine endothelial 1G11cells[69] were starved for 24 hours before stimulation with recombinant FGF2 (3.0 pmol/L). At the indicated times, *Nkx2.5* and *tubulin* expression were evaluated by RT-PCR analysis.

Homozygous *fgfr1* mutation results in alterations of the expression of the other *fgfr* genes in EBs with a delayed upregulation of *fgfr2* and *fgfr3* and the lack of appearance of *fgfr4* transcripts. Also, *fgf8* upregulation was altered and *fgf10* was not expressed in homozygous EBs. Thus, the possibility exists that alterations in the expression of other member(s) of FGF/FGFR signaling consequent to *fgfr1* inactivation may affect heart development. Relevant to this point, previous observations had shown that both BMP2 and FGF4 or FGF2 are required to induce a full cardiac differentiation of nonprecardiac mesoderm in the chick embryo.[59] Also, *fgf8* expression is required for induction and patterning of myocardial precursors in zebrafish.[32] However, addition of BMP2 protein alone or together with FGF2 did not restore the capacity of *fgfr1*[−/−] EBs to form contractile cardiomyocyte foci in our experimental conditions (data not shown).

FGF/FGFR signaling plays important functions in mesoderm formation and development. In *Xenopus laevis*, FGF/FGFR signaling is required for the expression of several early mesodermal markers, the induction of posterior and ventral mesoderm, and for proper mesodermal maintenance during gastrulation.[60,61] Moreover, *fgfr1* and *fgfr2* transcripts are detectable in mouse egg cylinder and in the primitive ectoderm.[62] At later stages of development, the undifferentiated mesenchyme is a specific domain for *fgfr1* expression.[62] Also, the nascent mesoderm of homozygous *fgfr1* mutant mouse embryos differentiates into diverse mesodermal subtypes, but mesodermal patterning is aberrant.[15] Accordingly, the expression of some mesodermal markers, including *nodal*, *T(bra)*, and *SHH*, is altered in *fgfr1*[−/−] ES cells. Nevertheless, *fgfr1*-null mutation does not prevent the downregulation of the pluripotent cell marker *Oct4*, thus indicating that the general differentiation capacity of these cells is not fully impaired. Indeed, *fgfr1*[+/−] and *fgfr1*[−/−] EBs similarly express endothelial and hematopoietic markers between days 7 and 10 of differentiation and the skeletal muscle markers *myogenin* and *myoD* at day 16. This is in keeping with the ability of *fgfr1*-null embryos to form various mesodermal tissues including allantois, amnion, visceral yolk sac mesoderm, and blood.[14,15] Also, *fgfr1*[−/−] ES cells originate muscle cells when injected in nude mice to form teratomas[15] and residual muscle tissue forms in *heartless*-null *Drosophila* embryos.[63] In apparent contrast with our observations, a defective in vitro hematopoietic development has been described for *fgfr1*[−/−] EBs at early times of differentiation.[64]

Further experiments are required to elucidate the role of *fgfr1* in early endothelial/hematopoietic differentiation.

The *fgfr1*-null mutation appears to exert a rather selective effect on cardiomyocyte development in differentiating EBs. These conclusions are supported by the capacity of various FGF/FGFR signaling inhibitors to prevent cardiomyocyte development in differentiating *fgfr1*$^{+/-}$ ES cells without affecting the expression of the hematopoietic/endothelial marker *flk-1*. On the other hand, the capacity of the PKC activator PMA to partially rescue cardiomyocyte differentiation in *fgfr1*-null EBs points to the lack of an appropriate FGFR1-driven intracellular signaling as a major mechanism responsible for the impaired developmental process. Moreover, the ability of the MEK1/2 inhibitor U0126 to abolish PMA-triggered cardiomyocyte differentiation is in keeping with the cross-talk existing between PKC and the Ras/Raf-1/MEK/ERK signaling pathways,[54] both activated by FGFR1 engagement.[3] Interestingly, the lack of effect of the MEK1 inhibitor PD098059 point to a selective role for MEK2 in cardiomyocyte development. Also, our data implicate the PKCϵ isozyme in this developmental process, in keeping with its nuclear localization in ES-derived cardiomyocytes.[65] Further experiments are required for a detailed characterization of the cross-talk between PKC/MEK signaling pathways during heart formation.

In mice, FGFR1-null embryos are developmentally retarded and die during gastrulation (see earlier). FGFR2 mutation results instead in a later embryonic lethality characterized by the lack of a functional placenta and limb buds.[66] FGFR3-deficient mice are normal during gestation and exhibit bone alterations during postnatal development.[67] Finally, FGFR4-null animals are developmentally normal.[68] Thus, the different *fgfr* genes appear to exert distinct, nonoverlapping functions during development. Our results demonstrate a nonredundant role for *fgfr1* in cardiomyocyte development in vitro.

Acknowledgments

References

1. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. *Annu Rev Biochem*. 1993;62:453–481.
2. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. *Cell*. 1990;61:203–212.
3. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. *Endocr Relat Cancer*. 2000;7:165–197.
4. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. *Adv Cancer Res*. 1993;60:1–41.
5. Ornitz DM, Itoh N. Fibroblast growth factors. *Genome Biol*. 2001;2: REVIEWS3005.
6. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. *Mol Cell Biol*. 1996;16:977–989.
7. Larsson H, Klint P, Landgren E, Claesson-Welsh L. Fibroblast growth factor receptor-1–mediated endothelial cell proliferation is dependent on the Src homology (SH) 2/SH3 domain-containing adaptor protein Crk. *J Biol Chem*. 1999;274:25726–25734.
8. Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W, Dionne CA, Jaye M, Rubinstein M, Schlessinger J. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. *Mol Cell Biol*. 1991;11:5068–5078.
9. Cross MJ, Lu L, Magnusson P, Nyqvist D, Holmqvist K, Welsh M, Claesson-Welsh L. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. *Mol Biol Cell*. 2002;13:2881–2893.
10. Divecha N, Irvine RF. Phospholipid signaling. *Cell*. 1995;80:269–278.
11. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. *Cell*. 1997;89: 693–702.
12. Hadari YR, Kouhara H, Lax I, Schlessinger J. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. *Mol Cell Biol*. 1998;18:3966–3973.
13. Xu X, Weinstein M, Li C, Deng C. Fibroblast growth factor receptors (FGFRs) and their roles in limb development. *Cell Tissue Res*. 1999;296: 33–43.
14. Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. *Genes Dev*. 1994;8:3032–3044.
15. Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM, Leder P. Murine FGFR-1 is required for early postimplantation growth and axial organization. *Genes Dev*. 1994;8:3045–3057.
16. Ciruna BG, Schwartz L, Harpal K, Yamaguchi TP, Rossant J. Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. *Development*. 1997;124:2829–2841.
17. Deng C, Bedford M, Li C, Xu X, Yang X, Dunmore J, Leder P. Fibroblast growth factor receptor-1 (FGFR-1) is essential for normal neural tube and limb development. *Dev Biol*. 1997;185:42–54.
18. Partanen J, Schwartz L, Rossant J. Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos. *Genes Dev*. 1998;12: 2332–2344.
19. Mohun T, Sparrow D. Early steps in vertebrate cardiogenesis. *Curr Opin Genet Dev*. 1997;7:628–633.
20. Sugi Y, Lough J. Anterior endoderm is a specific effector of terminal cardiac myocyte differentiation of cells from the embryonic heart forming region. *Dev Dyn*. 1994;200:155–162.
21. Nascone N, Mercola M. An inductive role for the endoderm in Xenopus cardiogenesis. *Development*. 1995;121:515–523.
22. Schultheiss TM, Xydas S, Lassar AB. Induction of avian cardiac myogenesis by anterior endoderm. *Development*. 1995;121:4203–4214.
23. Sugi Y, Sasse J, Lough J. Inhibition of precardiac mesoderm cell proliferation by antisense oligodeoxynucleotide complementary to fibroblast growth factor-2 (FGF-2). *Dev Biol*. 1993;157:28–37.
24. Logan M, Mohun T. Induction of cardiac muscle differentiation in isolated animal pole explants of *Xenopus laevis* embryos. *Development*. 1993;118:865–875.
25. Lough J, Barron M, Brogley M, Sugi Y, Bolender DL, Zhu X. Combined BMP-2 and FGF-4, but neither factor alone, induces cardiogenesis in non-precardiac embryonic mesoderm. *Dev Biol*. 1996;178:198–202.
26. Bodmer R. The gene tinman is required for specification of the heart and visceral muscles in Drosophila. *Development*. 1993;118:719–729.
27. Beiman M, Shilo BZ, Volk T. Heartless, a Drosophila FGF receptor homolog, is essential for cell migration and establishment of several mesodermal lineages. *Genes Dev*. 1996;10:2993–3002.
28. Gisselbrecht S, Skeath JB, Doe CQ, Michelson AM. heartless encodes a fibroblast growth factor receptor (DFR1/DFGF-R2) involved in the directional migration of early mesodermal cells in the Drosophila embryo. *Genes Dev*. 1996;10:3003–3017.
29. Frasch M. Induction of visceral and cardiac mesoderm by ectodermal Dpp in the early Drosophila embryo. *Nature*. 1995;374:464–467.
30. Peters KG, Werner S, Chen G, Williams LT. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. *Development*. 1992;114: 233–243.
31. Wanaka A, Milbrandt J, Johnson EM, Jr. Expression of FGF receptor gene in rat development. *Development*. 1991;111:455–468.

32. Reifers F, Walsh EC, Leger S, Stainier DY, Brand M. Induction and differentiation of the zebrafish heart requires fibroblast growth factor 8 (fgf8/acerebellar). *Development*. 2000;127:225–235.

33. Desbaillets I, Ziegler U, Groscurth P, Gassmann M. Embryoid bodies: an in vitro model of mouse embryogenesis. *Exp Physiol*. 2000;85:645–651.

34. Maltsev VA, Rohwedel J, Hescheler J, Wobus AM. Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinus nodal, atrial and ventricular cell types. *Mech Dev*. 1993;44:41–50.

35. Wobus AM. Potential of embryonic stem cells. *Mol Aspects Med*. 2001; 22:149–164.

36. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem*. 1987;162:156–159.

37. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. *J Clin Invest*. 1999;103:697–705.

38. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. *Science*. 1988; 242:1412–1415.

39. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. *Circ Res*. 2002;91:189–201.

40. Evans SM. Vertebrate tinman homologues and cardiac differentiation. *Semin Cell Dev Biol*. 1999;10:73–83.

41. Biben C, Harvey RP. Homeodomain factor Nkx2-5 controls left/right asymmetric expression of bHLH gene eHand during murine heart development. *Genes Dev*. 1997;11:1357–1369.

42. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C, Leiden JM. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. *Genes Dev*. 1997;11: 1048–1060.

43. Bao ZZ, Bruneau BG, Seidman JG, Seidman CE, Cepko CL. Regulation of chamber-specific gene expression in the developing heart by Irx4. *Science*. 1999;283:1161–1164.

44. Srivastava D, Cserjesi P, Olson EN. A subclass of bHLH proteins required for cardiac morphogenesis. *Science*. 1995;270:1995–1999.

45. Lyons GE, Schiaffino S, Sassoon D, Barton P, Buckingham M. Developmental regulation of myosin gene expression in mouse cardiac muscle. *J Cell Biol*. 1990;111:2427–2436.

46. Edmondson DG, Lyons GE, Martin JF, Olson EN. Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. *Development*. 1994;120:1251–1263.

47. Olson EN, Perry M, Schulz RA. Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. *Dev Biol*. 1995; 172:2–14.

48. Schuh AC, Faloon P, Hu QL, Bhimani M, Choi K. In vitro hematopoietic and endothelial potential of flk-1(−/−) embryonic stem cells and embryos. *Proc Natl Acad Sci U S A*. 1999;96:2159–2164.

49. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. *Development*. 1998; 125:725–732.

50. Young PE, Baumhueter S, Lasky LA. The sialomucin CD34 is expressed on hematopoietic cells and blood vessels during murine development. *Blood*. 1995;85:96–105.

51. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. *Science*. 1997;276: 955–960.

52. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. Identification of a novel inhibitor of

53. Bost F, Caron L, Marchetti I, Dani C, Le Marchand-Brustel Y, Binetruy B. Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. *Biochem J*. 2002;361: 621–627.

54. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. *Mol Cell Biol*. 1998;18:790–798.

55. Kuchera S, Barth H, Jacobson P, Metz A, Schaechtele C, Schrier D. Anti-inflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H- pyrrole-2, 5-dione monohydrochloride (GF109203X) in the PMA-mouse ear edema model. *Agents Actions*. 1993;39 Spec No:C169–C173.

56. Dorn GW II, Mochly-Rosen D. Intracellular transport mechanisms of signal transducers. *Annu Rev Physiol*. 2002;64:407–429.

57. Yamagishi H, Yamagishi C, Nakagawa O, Harvey RP, Olson EN, Srivastava D. The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac ventricle formation. *Dev Biol*. 2001;239:190–203.

58. Biben C, Weber R, Kesteven S, Stanley E, McDonald L, Elliott DA, Barnett L, Koentgen F, Robb L, Feneley M, Harvey RP. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. *Circ Res*. 2000;87:888–895.

59. Barron M, Gao M, Lough J. Requirement for BMP and FGF signaling during cardiogenic induction in non-precardiac mesoderm is specific, transient, and cooperative. *Dev Dyn*. 2000;218:383–393.

60. Amaya E, Musci TJ, Kirschner MW. Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. *Cell*. 1991;66:257–270.

61. Amaya E, Stein PA, Musci TJ, Kirschner MW. FGF signalling in the early specification of mesoderm in Xenopus. *Development*. 1993;118: 477–487.

62. Orr-Urtreger A, Givol D, Yayon A, Yarden Y, Lonai P. Developmental expression of two murine fibroblast growth factor receptors, flg and bek. *Development*. 1991;113:1419–1434.

63. Michelson AM, Gisselbrecht S, Zhou Y, Baek KH, Buff EM. Dual functions of the heartless fibroblast growth factor receptor in development of the Drosophila embryonic mesoderm. *Dev Genet*. 1998;22: 212–229.

64. Faloon P, Arentson E, Kazarov A, Deng CX, Porcher C, Orkin S, Choi K. Basic fibroblast growth factor positively regulates hematopoietic development. *Development*. 2000;127:1931–1941.

65. Ventura C, Zinellu E, Maninchedda E, Fadda M, Maioli M. Protein kinase C signaling transduces endorphin-primed cardiogenesis in GTR1 embryonic stem cells. *Circ Res*. 2003;92:617–22.

66. Xu X, Weinstein M, Li C, Naski M, Cohen RI, Ornitz DM, Leder P, Deng C. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. *Development*. 1998;125:753–765.

67. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat Genet*. 1996;12:390–397.

68. Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. *Development*. 1998;125:3615–3623.

69. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F, Garlanda C, Ramponi S, Mantovani A, Vecchi A. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. *Arterioscler Thromb Vasc Biol*. 1997;17: 1599–1604.

mitogen-activated protein kinase kinase. *J Biol Chem*. 1998;273: 18623–18632.

Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development

Patrizia Dell'Era, Roberto Ronca, Laura Coco, Stefania Nicoli, Marco Metra and Marco Presta

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circres.ahajournals.org/content/93/5/414

Data Supplement (unedited) at:

http://circres.ahajournals.org/content/suppl/2003/09/03/93.5.414.DC1

Expanded Materials and Methods

Reagents

SU5402 and bisindolylmaleimide I (GF109) were from Calbiochem; phorbol-12-myristate-13-acetate (PMA) and PD098059 were from Sigma; U0126 was from Promega. Antennapedia-conjugated PKC translocation inhibitors were gifted by D. Mochly-Rosen (Stanford University, CA).

EB immunostaining.

ES cell aggregates at day 10 of differentiation were transferred to microtubes, washed with PBS and fixed with 3% paraformaldehyde for 1 hour at 4°C. After extensive washes with PBS, aggregates were suspended subsequently in 12% saccharose/PBS (1h at 4°C), 15% saccharose/PBS (1h at 4°C), and 18% saccharose/PBS (overnight at 4°C). The day after, the solution was replaced by Tissue-Tek® O.C.T. compound (Miles Scientific) for 2 min. and immediately frozen in liquid nitrogen. The samples were placed in cryostat, and 7 μM thick sections were collected onto pre-coated gelatin glass slides. Then, slides were processed with TSA™ Biotin System (Perkin Elmer Life Science) following manufacturer's instructions. Monoclonal antibody BA-G5 directed against cardiac α–myosin heavy chain (a gift from S. Schiaffino, University of Padova, Italy) was used at 1:2000 dilution. At the end of the procedure, slides were stained for 10 minutes with a 30 μmol/L solution of 4',6-Diamidino-2-phenylindole (DAPI, Sigma), mounted in 20% Mowiol (Sigma), and observed under a fluorescence microscope.

Table 1. Specific PCR primers utilized in the present study.

| Target gene	Forward PCR oligonucleotide	Reverse PCR oligonucleotide	N° of cycles
β-major	5'-CACAACCCCAGAAACAGACA	5'-CTGACAGATGCTCTCTTGGG	25
BMP2	5'-GTTTGTGTTTGGCTTGACGC	5'-AGACGTCCTCAGCGAATTTG	23
BMP4	5'-ACCAATGGAGCCATTCCGTAG	5'-CTCATGTAATCCGGAATGACGG	26
CD31	5'-ATCAGCACCACCTCGAAAAGC	5'-GGTGTAGTGTCCACTGTACTCGACC	25
CD34	5'-GTTACCTCTGGGATCCCTTCAGGCTC	5'-CTCCAGAGGTGACCAATGCAATAAG	29
c-kit	5'-GCTCATAAATGGCATGCTCC	5'-AAGTTGCGTCGGGTCTATGT	28
e-HAND	5'-TTCCCTCCTGCCAATTGGCT	5'-GGGCCAAACAGGAAGGGTTCGT	24
cripto	5'-CGGAATTCCAGTTGCACACTGGGATTT	5'-CGGGATCCGTACGCGATCGGTCTTCC	23
fgf2	5'-CCTTCCCACCAGGCCACTTCAA	5'-GGTCCCGTTTTGGATCCGAGTTT	26
fgf4	5'-ACAGTCTTCTGGAGCTCTCTCCG	5'-TCACAGTCTAGGAAGGAAGTGGGTTA	30
fgf8	5'-GTTGCACTTGCTGGTTCTCTGCCT	5'-CGGGGTAGTTTGGGGCTGGATT	26
fgf10	5'-CTGACACATTGTGCCTCAGCCTTTC	5'-TGCCATTGTGCTGCCAGTTAAAAGA	33
fgfr-1	5'-GCTGACTCTGGCCTCTACGCT	5'-CAGGATCTGGACATACGGCAA	33
fgfr-2	5'-CTCCTTCAGTTTAGTTGAGGATACCA	5'-GAAGATCCAAGTTTCACTGTCTACCG	26
fgfr-3	5'-GAAGAATGGCAAAGAATTCCGAG	5'-CCTCTAGCTCCTTGTCGGTGG	28
fgfr-4	5'-GAACTCTCTGGGTAGCATTCGCT	5'-TGTCTGTTGTCTTGAGGACTTGTACG	32
flk-1	5'-TAGGTGCCTCCCCATACCCTGG	5'-TGGCCGGCTCTTTCGCTTACTG	25
GATA4	5'-CGAGATGGGACGGGACACTAC	5'-TGAGTGACAGGAGATGCATAGCC	25
Irx4	5'-TTAGTACCCGCCCCCAGATTGC	5'-GTGAGCTGAAGACGCCCTTCCA	26
Mef2c	5'-GGGGAGAAAAAGATTCAGATTACGA	5'-TGGTAAAGTAGGAGTTGCTACGGAAA	26
MHC-α	5'-CTGCTGGAGAGGTTATTCCTCG	5'-GGAAGAGTGAGCGGCGCATCAAGG	25
MHC-β	5'-TGCAAAGGCTCCAGGTCTGAGGGC	5'-GCCAACACCAACCTGTCCAAGTTC	23
MLC-2V	5'-GCCAAGAAGCGGATAGAAGG	5'-CTGTGGTTCAGGGCTCAGTC	23
MyoD	5'-CACTACAGTGGCGACTCAGA	5'-TGCTGCTGCAGTCGATCTCT	28
myogenin	5'-AGCTCCCTCAACCAGGAGGA	5'-GGGCTCTCTGGACTCCATCT	33
Nkx2-5	5'-CAGAACCGTCGCTACAAGTGC	5'-CGAGACACCAGGCTACGTCAAT	28
Nodal	5'-TTCCTTCTCAGGTCACGTTTGC	5'-GGTGGGGTTGGTATCGTTTCA	25
Oct4	5'-CAGGAGTTCAAGGGCAGCTTGT	5'-ATTAGGAGGAGGGGGTGCAGAG	33
shh	5'-CTGCTGCTGCTGGCCAGATGTT	5'-AAGTCCTTCACCAGCTTGGTGCCG	26
T(bra)	5'-ATCAAGGAAGGCTTTAGCAAATGGG	5'-GAACCTCGGATTCACATCGTGAGA	28
tubulin	5'-TCACTGTGCCTGAACTTACC	5'-GGAACATAGCCGTAAACTGC	20
ve-cad	5'-TTTGGAATCAAATGCACATCGA	5'-TGCTGTACTTGGTCATCCGGTT	29

Figure 1. Titration analysis of PCR amplification of *tubulin* and *Nkx2.5* mRNAs. Complementary DNAs were synthesized from a dilution series of total cellular RNA (0.0313, 0.0625, 0.125, 0.25, 0.5, 1.0, and 2.0 µg/20 µl). Samples were extracted from both *fgfr1*[+/-] and *fgfr1*[-/-] ES cells at day 9th of differentiation. cDNAs were amplified for the indicated PCR cycles and products were quantified by computerized image analysis of the agarose gel.